Dyadic International (DYAI US): Synthetic Expert Call Transcript (14 Sep 2026)
The C1 platform's superior biophysical metrics (12 g/L yields and 12-to-14-day inoculation timelines) are structurally offset by high switching...
90 Views
IPO Databook: Dyadic International (DYAI US) - Sep 2026
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Florida, developing and commercializing precision-engineered,...
97 Views
DYAI: Second Quarter Results
Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...
93 Views
Primer: Dyadic International (DYAI US) - Aug 2026
Dyadic International is a biotechnology company centered on its proprietary C1 and Dapibus™ microbial expression platforms, designed for...
98 Views
DYAI: First Quarter Results
Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...
95 Views